Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
IP-BCD Variant #01 | — | R 30 531 | 35d | — | — | — | — | — |
MAPI Variant #01 | — | R 30 134 | 42d | — | — | — | — | — |
M-EI Variant #01 | — | R 24 181 | 7d | — | — | — | — | — |
Cisplatin, Epirubicin, Ifosfamide Variant #01 | — | R 13 819 | 21d | — | — | — | — | — |
MA-BCD/AP Variant #01 | — | R 13 352 | 7d | — | — | — | — | — |
M-BCD Variant #01 | — | R 11 925 | 35d | — | — | — | — | — |
MAP N/A - protocol | — | R 8 253 | 56d | — | — | — | — | — |
IE N/A - secondary systemic drug | — | R 5 678 | 28d | — | — | — | — | — |
MAPIE N/A - protocol | — | R 5 178 | 69d | — | — | — | — | — |
Cisplatin and Doxorubicin N/A - secondary systemic drug | — | R 3 077 | 21d | — | — | — | — | 1 |
MA Variant #01 | — | R 1 912 | 28d | — | — | — | — | — |
Doxorubicin monotherapy Variant #10 | — | R 1 293 | 21d | ~5.8 mo | ~19.0 mo | ~9 | ~R 11 639 PFS proxy · indirect | 7 |
Methotrexate and Vincristine N/A - intrathecal component | — | R 1 127 | 56d | — | — | — | — | — |
Observation Partial | — | — | — | — | ~97.6 mo | — | — | 3 |
14 of 14 regimens shown